Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIIR 561 CL (Irampanel) in Healthy Men
NCT02222974Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 1999
- Primary completion
- Aug 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in acute stroke and cerebral ischemia comparing BIIR 561 CL with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events up to 9 days, Number of subjects with clinically significant findings in vital functions up to 9 days and 3 more. Started Jan 1999; status: completed.
02
Drugs
irampanel
03
Conditions
acute strokecerebral ischemia
Beyond the preview
Go deeper on NCT02222974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222974.